Table 5.
Univariate and multivariate analysis of clinical characteristics and treatment related to in-hospital mortality
| Univariate | Multivariate | |||
|---|---|---|---|---|
| OR (CI 95%) | p | OR (CI 95%) | p | |
| Male (yes) | 1.1 (0.3–4.02) | 0.88 | – | – |
| Age > 60 years | 7.03 (1.34–36.82) | 0.017 | 4.16 (0.65–26.6) | 0.13 |
| Hypertension history | 1.85 (0.6–5.66) | 0.28 | – | – |
| Diabetes | 3.09 (0.72–13.32) | 0. 17 | – | – |
| COPD | 3.08 (0.72–13.3) | 0.182 | – | – |
| CKD III | 6.86 (0.76–61.67) | 0.1 | – | – |
| BMI > 30 | 0.5 (0.1–2.41) | 0.46 | – | – |
| Presence of one or more comorbidities | 4.52 (1.2–16.97) | 0.03 | 3.29 (0.69–15.46) | 0.13 |
| ARB history | 1.67 (0.35–7.84) | 1 | – | – |
| ACEI history | 1.84 (0.47–7.25) | 0.38 | – | – |
| SOFA ≥ 8 at AKI | 2.58(0.8435–7.93) | 0.09 | – | – |
| Non-renal SOFA ≥ 7 at AKI | 1.1 (0.3–4.02) | 0.88 | – | – |
| Mechanical ventilation | 0.6 (0.13–2.82) | 0.7 | – | – |
| PA/FIO2 admission < 200 mmHg | 0.42 (0.12–1.47) | 0.17 | – | – |
| PA/FIO2 at AKI < 200 mmHg | 0. 85 (0.27–2.63) | 0.77 | – | – |
| AKIN 3 at diagnosis time | 0.4 (0.09–1.79) | 0.28 | – | – |
| RRT (yes) | 1.08 (0.32–3.6) | 0.89 | – | – |
| RRT more than 7 days | 1.25 (0.16–9.92) | 1 | – | – |
| AKI recovery | 0.11 (0.03–0.42) | 0.001 | 0.13 (0.03–0.54) | 0.005 |
| Vasoactive drugs at AKIN | 0.75 (0.22–2.58) | 065 | – | – |
| Corticosteroids | 1.12 (0.34–3.63) | 0.85 | – | – |
| Tocilizumab | 0.63 (0.21–1.88) | 0.4 | – | – |
| Lopinavir/Ritonavir | 0.52 (0.04–6.13) | 1 | – | – |
| Thrombotic event | 0.55 (0.13–2.24) | 0.49 | – | – |
AKI acute kidney injury, RRT renal replacement therapy, CRRT continuous renal replacement therapy, IQR interquartile range, SD standard deviation, GFR glomerular filtration rate, SOFA Sequential Organ Failure Assessment score, PaFiO2 arterial blood oxygen pressure, MV mechanical ventilation, BMI Body Mass Index, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, CKD chronic kidney disease, ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin II receptor blockers, PaFiO2 arterial blood oxygen pressure, FiO2 fraction of inspired oxygen